Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-17T22:34:52.641Z Has data issue: false hasContentIssue false

Authors' reply

Published online by Cambridge University Press:  02 January 2018

Anick Bérard
Affiliation:
Faculty of Pharmacy, University of Montreal, Pavillon Jean-Coutu, Local 2244, Montreal, and Medications and Pregnancy Research Center, Sainte Justine Hospital, Montreal, Canada. Email: anick.berard@umontreal.ca
Élodie Ramos
Affiliation:
Faculty of Pharmacy, University of Montreal, Pavillon Jean-Coutu, Local 2244, Montreal, and Medications and Pregnancy Research Center, Sainte Justine Hospital, Montreal, Canada. Email: anick.berard@umontreal.ca
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2008 

The nested case–control approach that we used is the most effective design to study rare outcomes such as major congenital malformations. Reference Ramos, St-André, Rey, Oraichi and Bérard1,Reference Hernández-Díaz, Hernán, Meyer, Werler and Mitchell2 This is even truer since it was performed in a well-established cohort of women with pre-pregnancy diagnosed psychiatric disorders. We disagree with Rajkumar & Jacob that a cohort approach would have been better, based on the fact that it lacks power for research in perinatal pharmacoepidemiology. This was clearly apparent when several small human cohort studies published in the 1990s did not suggest an overall increased risk for birth defects with first-trimester exposure to any selective serotonin reuptake inhibitors but later studies with more efficient designs such as the case–control approach started showing low-to-moderate increased risks for the more commonly occurring birth defects such as heart defects, neural tube defects and oral clefts. Therefore, using a cohort approach would have resulted again in a null finding, contrary to Rajkumar & Jacob's comments.

We excluded pregnancies ending with abortion or miscarriage per design since malformation outcomes of these foetuses were not available in the Quebec Pregnancy Registry. We agree that this resulted in prevalent cases of malformations in our study but this is highly comparable to studies performed in similar populations. We do not, however, agree that this methodological choice resulted in biasing our study estimates towards the null. Indeed, although Hemels et al Reference Hemels, Einarson, Koren, Lanctôt and Einarson3 reported an association between antidepressant use during pregnancy and risk of spontaneous abortion, this was based on women's self-report and likely resulted in an overestimation of the rate of miscarriage and an underestimation of the rate of abortion, hence a significant association.

Major congenital malformations are structural abnormalities that affect the way a person looks and require medical and/or surgical treatment. Minor defects are abnormalities that do not cause serious health or social problems. Major defects were the focus of interest in our study and, although the risk of minor malformations is interesting, it is a different research question. Several other authors have previously made this distinction. Reference Simon, Cunningham and Davis4,Reference Chambers, Johnson, Dick, Felix and Jones5

We agree that results from observational studies always need to be interpreted with caution. However, given that from an ethical point of view it is almost impossible to randomise pregnant women to receive medications not known to be safe for the foetus, the collection and follow-up of observational data is the only ethical way to close the knowledge gap between the limited value of animal studies and human pregnancy exposures.

Finally, our study was not designed to look at the effect of the duration of specific antidepressants on the risk of specific major congenital malformations. Therefore, we only looked at duration of antidepressant use during the first trimester of gestation and its risk for major congenital malformations, all types and all malformations combined. Results should be interpreted in this context.

Footnotes

Declaration of interest

This study was supported by the Fonds de la Recherche en Santé du Québec (FRSQ, grant number: 6263), the Réseau Québécois de Recherche sur l'Usage des Médicaments (RQRUM), and the FRSQ network for the well-being of children.

References

1 Ramos, E, St-André, M, Rey, E, Oraichi, D, Bérard, A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychitary 2008; 192: 344–50.Google ScholarPubMed
2 Hernández-Díaz, S, Hernán, MA, Meyer, K, Werler, MM, Mitchell, AA. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 2003; 158: 385–91.CrossRefGoogle ScholarPubMed
3 Hemels, MEH, Einarson, A, Koren, G, Lanctôt, KL, Einarson, TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005; 39: 803–9.CrossRefGoogle ScholarPubMed
4 Simon, GE, Cunningham, ML, Davis, RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61.CrossRefGoogle ScholarPubMed
5 Chambers, CD, Johnson, KA, Dick, LM, Felix, RJ, Jones, KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–5.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.